B7-H4 fusion proteins and methods of use thereof

A method for reducing inflammation in a human subject, the method comprising treating the subject according to a dosage regimen comprising intravenous administration of one or more doses of a fusion protein comprising the amino acid sequence of SEQ ID NO:

• 130, wherein the dosage regimen is effective to achieve at least a 1.0 μg/ml concentration of the fusion protein in the subject post administration, and wherein the dosage regimen increases the ratio of regulatory T cells (Tregs) relative to total CD4+ cells and reduces inflammation in the subject for at least a week post administration.

A method for treating an autoimmune disorder in a human subject, the method comprising treating the subject according to a dosage regimen comprising intravenous administration of one or more doses of a fusion protein comprising a B7-H4 polypeptide comprising the IgV domain of SEQ ID NO:

• 63 or SEQ ID NO:
• 64 fused to a second polypeptide or fused to a linker peptide fused to a second polypeptide, wherein the dosage regimen is effective to achieve at least a 1.0 μg/ml concentration of the fusion protein in the subject post administration, and wherein the dosage regimen increases the ratio of regulatory T cells (Tregs) relative to total CD4+ cells and reduces inflammation in the subject for at least a week post administration.

A method for treating an autoimmune disorder in a human subject, the method comprising treating the subject according to a dosage regimen comprising intravenous administration of one or more doses of a fusion protein comprising the amino acid sequence of SEQ ID NO:

• 130, wherein the dosage regimen is effective to achieve at least a 1.0 μg/ml concentration of the fusion protein in the subject post administration, and wherein the dosage regimen increases the ratio of regulatory T cells (Tregs) relative to total CD4+ cells and reduces inflammation in the subject for at least a week post administration.